- Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring?
Mara S. Serafini et al, 2024, The Journal of Liquid Biopsy CrossRef - Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
Joanne Chiu et al, 2023, BMC Medicine CrossRef - Understanding the Landscape of Clinically Available Molecular Testing
Julia A. Elvin, 2024, Surgical Oncology Clinics of North America CrossRef - Glycoproteomics-Based Liquid Biopsy: Translational Outlook for Colorectal Cancer Clinical Management in Southeast Asia
Gaayathri Kumarasamy et al, 2023, Future Oncology CrossRef - Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay
Tadayoshi Hashimoto et al, 2024, International Journal of Clinical Oncology CrossRef